Fig. 1 · Structure

Documents & Downloads

PF-00562271

Cat. No. A12580 CAS 939791-38-5

FAK inhibitor

PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively.

In Stock

Publications for PF-00562271

1 publication citing this product

  1. Dai Sonoda, .et al. , Oncol Rep, 2022, Jan;47(1):19 PMID: 34796907

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In KU-Lu-MPPt3 CS lung adenocarcinoma cells, PF-00562271 reduced FAK Tyr397 phosphorylation while increasing Akt Ser473 phosphorylation. The authors reported a cellular signaling response; the experiment does not determine biochemical selectivity or an IC50. The tested material was named PF-00562271 from AdooQ, with salt form unspecified. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
FAK IC50 1.5nM
PYK2 IC50 13nM
CDK2/CyclinE IC50 30nM
CDK3/CyclinE IC50 47nM
CDK1/CyclinB IC50 58nM
CDK7/CyclinH/MAT1 IC50 97nM
FLT3 IC50 97nM
GSK-3α IC50 101nM
CDK5/p35 IC50 120nM
GSK-3β IC50 133nM
AuroraA IC50 145nM
CDK2/CyclinA IC50 227nM
YES IC50 294nM
MAPK1 IC50 340nM
Fyn IC50 377nM
LCK IC50 408nM
IGF-1R IC50 >500nM
PKA IC50 620nM
c-Src IC50 797nM
CDK4 IC50 >1μM
CDK6/CyclinD2 IC50 >1μM
Chk1 IC50 >1μM
Chk2 IC50 >1μM
EGFR IC50 >1μM
EphB2 IC50 >1μM
FGFR3 IC50 >1μM
Abl IC50 >1μM
Fms IC50 >1μM
IKKα IC50 >1μM
IKKβ IC50 >1μM
JNK1α1 IC50 >1μM
MEK1 IC50 >1μM
p70S6K IC50 >1μM
PKBα IC50 >1μM
PKBβ IC50 >1μM
PKBγ IC50 >1μM
PKCα IC50 >1μM
PKCβ2 IC50 >1μM
PKCδ IC50 >1μM
TrkB IC50 >2.5μM
PDGFRβ IC50 >3μM

41 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A549 GI50 2.1 μM Antiproliferative activity against human A549 cells after 2 days by spectrophotometric analysis [PMID: 30340900]
HeLa GI50 1.7 μM Antiproliferative activity against human HeLa cells after 2 days by spectrophotometric analysis [PMID: 30340900]
HepG2 GI50 1.2 μM Antiproliferative activity against human HepG2 cells after 2 days by spectrophotometric analysis [PMID: 30340900]
OVCAR-3 GI50 1.8 μM Antiproliferative activity against human OVCAR3 cells after 2 days by spectrophotometric analysis [PMID: 30340900]
U-87MG ATCC GI50 3.7 μM Antiproliferative activity against human U87MG cells after 2 days by spectrophotometric analysis [PMID: 30340900]

PF-00562271 Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of PF-00562271 from 3 published references. In vitro models include KU-Lu-MPPt3 clumpy and suspended (CS) cells; KU-Lu-MPPt3 CS cells on collagen-coated 96-well plates.

PF-00562271 In Vitro Studies

PF-00562271 suppressed the WST-8 proliferation response of collagen-plated KU-Lu-MPPt3 CS cells during a four-day assay. The paper does not specify the PF-00562271 concentration for this experiment, preventing a dose-specific potency claim. [1]

In pancreatic MPanc-96 and MAD08-608 cultures, the authors reported that PF-562,271 up to 1 µM did not inhibit proliferation or enhance gemcitabine-mediated growth inhibition. The growth panel extends to 10 µM, where the cell-number signal falls; the negative result applies to the stated lower concentration range and culture conditions. [2]

In a three-dimensional PDAC 608 tumor microenvironment system, 5.8 µM PF-562,271 for three days reduced total tumor/stellate cell-number signal by 49% and tumor-specific EdU incorporation by 67% versus DMSO. These endpoints measure different cell populations. This experiment supports activity in that multicellular model, without establishing the cause of differences from two-dimensional culture. [3]

FAK and Akt phosphorylation in lung adenocarcinoma cells

Cell-based study · KU-Lu-MPPt3 clumpy and suspended (CS) cells [1]

PF-00562271 reduced p-FAK/total FAK while increasing p-Akt/total Akt relative to control. Akt inhibitor X was a separate comparator, not a combination treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
FAK Tyr397 and Akt Ser473 phosphorylation normalized to corresponding total proteinDirectional response p-FAK decreased; p-Akt increased; mean ± SE, three independent experiments[1]

Literature-Reported Treatment Conditions

Method
Western blotting with p-FAK Tyr397, p-Akt Ser473, total FAK, total Akt and actin controls.
Reported limits
PF-00562271 concentration, signaling exposure duration, vehicle, counterion and lot are not specified in the relevant main-text methods/caption.
Methods and source locations

Compound reported in the paper: PF-00562271

Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.

Figure 5A/B; Antibodies and inhibitors; Western blot analysis; Results: Involvement of Akt and FAK in adhesion and proliferation

FAK Tyr397 and Akt Ser473 phosphorylation normalized to corresponding total protein: Immunoblot and band quantification; no exact bar-height values inferred. — Figure 5A/B and caption; Western blot analysis

Proliferation response in KU-Lu-MPPt3 CS cells

Cell-based study · KU-Lu-MPPt3 CS cells on collagen-coated 96-well plates [1]

Untreated cells expanded, whereas PF-00562271 suppressed the WST-8 proliferation signal over the four-day assay. This readout does not establish cell death.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
WST-8 proliferation ratio compared with untreated cultureQualitative growth inhibition Growth suppressed; mean ± SE, three independent experiments[1]

Literature-Reported Treatment Conditions

Exposure duration
4 days
Method
WST-8/CCK-8 absorbance at 450 nm; untreated control and separate Akt inhibitor X comparator.
Reported limits
PF-00562271 concentration and vehicle are not specified in the relevant main text/caption; no IC50 can be assigned.
Methods and source locations

Compound reported in the paper: PF-00562271

Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.

Figure 5C and caption; Cell proliferation assay; Results: Involvement of Akt and FAK in adhesion and proliferation

WST-8 proliferation ratio compared with untreated culture: WST-8 readout; no exact values digitized from the time course. — Figure 5C and caption; Cell proliferation assay

Limited antiproliferative activity in pancreatic cell cultures

Cell-based study · MPanc-96 and MAD08-608 pancreatic ductal adenocarcinoma cultures, as described jointly in Results; Figure 3C is the representative main-text growth panel. [2]

The Results report no proliferation inhibition by PF-562,271 at up to 1 µM, alone or with gemcitabine, despite inhibition of FAK signaling/migration at lower concentrations in separate assays. Figure 3C includes a 10 µM point with a lower cell-number signal; the negative finding is therefore restricted to ≤1 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Pancreatic cell proliferation alone or with gemcitabineNegative result No effect reported at PF-562,271 concentrations up to 1 µM; no enhancement of gemcitabine growth inhibition under these conditions[2]

Literature-Reported Treatment Conditions

Treatment concentration
PF-562,271: 0.001, 0.01, 0.1, 1 and 10 µM in Figure 3C; negative proliferation conclusion restricted to ≤1 µM.
Method
CyQuant cell-number assay in 1% FBS-containing medium.
Co-treatment
Parallel gemcitabine series: 1, 10 and 100 ng/mL; PF-562,271 tested alone and with gemcitabine.
Reported limits
Proliferation exposure duration, vehicle composition and replicate number are not specified in the selected main-text assay/caption. MAD08-608 supplemental plot was not retrieved.
Methods and source locations

Compound reported in the paper: PF-562,271

Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.

Figure 3C and caption; Results: PDA cell receptor signaling, migration and invasion; Transwell migration, invasion and proliferation assays

Pancreatic cell proliferation alone or with gemcitabine: CyQuant; figure error bars denote standard error; n not specified in caption. — Results paragraph beginning “We evaluated the effects”; Figure 3C; proliferation methods

PF-562,271 response in a pancreatic tumor microenvironment system

Cell-based study · PDAC 608 patient-derived tumor cells with primary human pancreatic stellate cells and microvascular endothelial cells in a three-dimensional TMES under tumor-like hemodynamics. [3]

PF-562,271 reduced total tumor/stellate cell-number signal and tumor-specific EdU incorporation versus DMSO. These are complementary endpoints from one exposure experiment, not independent studies.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total tumor-plus-stellate cell number per unit areaReported reduction versus DMSO 49%; P=0.0004[3]
Tumor-specific proliferating fractionReported reduction versus DMSO 67%; P=0.00005[3]

Literature-Reported Treatment Conditions

Treatment concentration
5.8 µM PF-562,271
Exposure duration
3 days of treatment after 4 days of TMES growth
Method
PicoGreen total-cell DNA surrogate and EdU co-imaged with cytokeratin 18 for tumor-specific proliferation.
Vehicle
DMSO (0.058%)
Reported limits
Exact salt form, supplier and lot are not specified in selected main-text methods. TMES lacks immune cells; no clinical response to PF-562,271 was tested.
Methods and source locations

Compound reported in the paper: PF-562,271

Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.

Figure 5A/B and caption; PF-562,271 Results; Methods: Cell culture, Tumor Microenvironment System, Immunofluorescence

Total tumor-plus-stellate cell number per unit area: PicoGreen with standard curve; Figure 5 caption specifies N=3 with five independent measurements across each transwell replicate, not 15 independent biological replicates. — Figure 5A/caption and PF-562,271 Results

Tumor-specific proliferating fraction: EdU incorporation co-imaged with cytokeratin 18; N=3 with five measurements across each transwell replicate; EdU pulse for final 2 hours. — Figure 5B/caption; Methods: Tumor Microenvironment System and Immunofluorescence

PF-00562271 In Vivo Studies

In mice bearing orthotopic MPanc-96 tumors, PF-562,271 at 33 mg/kg twice daily by gastric lavage produced tumors 46 ± 8% smaller than vehicle controls after two weeks of treatment. Invasion and metastasis incidences also decreased. Adding gemcitabine did not significantly improve tumor volume over either drug alone. The paper does not identify the PF-562,271 salt form. [2]

PF-562,271 treatment in an orthotopic pancreatic tumor model

Animal study · Six-week-old male athymic nude mice bearing orthotopic MPanc-96 pancreatic tumors; randomized treatment groups. [2]

PF-562,271 monotherapy reduced tumor volume and the incidence of invasion/metastasis relative to vehicle. Combination with gemcitabine did not significantly improve tumor volume over either single agent.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MPanc-96 tumor volume after two weeks of treatmentReduction relative to vehicle 46 ± 8% smaller than control tumors[2]
Incidence of retroperitoneal invasion, liver metastasis and peritoneal metastasisAnimals with event / animals evaluated Control vs PF-562,271: retroperitoneal invasion 17/19 (89%) vs 4/19 (21%); liver metastasis 17/19 (89%) vs 8/19 (42%); peritoneal metastasis 19/19 (100%) vs 11/19 (58%); each P<0.05 vs control[2]
Tumor volume with combination compared with either single agentComparison limitation Combination tumors were smaller than control, but not significantly different from either drug alone[2]

Conditions shared by the study groups

Treatment course
Day 7 through day 21 after implantation
Vehicle
Composition not specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlReference groupComparator for tumor growth and invasion/metastasis.[2]
PF-562,271 alone
33 mg/kg
VehicleReduced tumor volume and invasion/metastasis incidence.[2]
Gemcitabine alone
10 mg/kg
VehicleTumors 53 ± 7% smaller than control in the Results; not significantly different from combination.[2]
PF-562,271 plus gemcitabine
PF-562,271 33 mg/kg; gemcitabine 10 mg/kg
Vehicle and each monotherapyNo significant additional tumor-volume reduction over either drug alone.[2]
Vehicle control
Model: MPanc-96 orthotopic tumors in male athymic nude mice
Reported limits: MRI cohort n not specified in Figure 4 caption; do not substitute Table 1 denominators.
PF-562,271 alone
Model: MPanc-96 orthotopic tumors in male athymic nude mice
Route: Gastric lavage
Frequency: Twice daily
Reported limits: MRI cohort n not specified in Figure 4 caption; do not substitute Table 1 denominators.
Gemcitabine alone
Model: MPanc-96 orthotopic tumors in male athymic nude mice
Route: Intraperitoneal
Frequency: Twice weekly
Reported limits: MRI cohort n not specified in Figure 4 caption; do not substitute Table 1 denominators.
PF-562,271 plus gemcitabine
Model: MPanc-96 orthotopic tumors in male athymic nude mice
Route: PF-562,271: gastric lavage; gemcitabine: intraperitoneal
Frequency: PF-562,271: twice daily; gemcitabine: twice weekly
Reported limits: MRI cohort n not specified in Figure 4 caption; do not substitute Table 1 denominators.
Methods and source locations

Compound reported in the paper: PF-562,271

Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.

Figure 4A/B and caption; Table 1 MPanc-96 rows; Orthotopic tumor model; PF-562,271 and gemcitabine treatment; Statistical analysis

MPanc-96 tumor volume after two weeks of treatment: Results give the reduction; Figure 4 error bars denote standard error. No exact MRI curve coordinates inferred. — Results: PF-562,271 Inhibition of Orthotopic Growth, Invasion, and Metastasis; Figure 4B

Incidence of retroperitoneal invasion, liver metastasis and peritoneal metastasis: Necropsy; categorical comparisons use Fisher’s exact test in statistical methods. Counts pertain to Table 1. — Table 1 MPanc-96 rows and footnote; Orthotopic tumor model; Statistical analysis

Tumor volume with combination compared with either single agent: MRI volume comparison; one-way ANOVA/Bonferroni analysis described for in-vivo groups. — Figure 4B; Results: PF-562,271 Inhibition of Orthotopic Growth, Invasion, and Metastasis; Statistical analysis

Vehicle control · Figure 4B; Orthotopic tumor model; treatment methods; associated Results

PF-562,271 alone · Figure 4B; Orthotopic tumor model; treatment methods; associated Results

Gemcitabine alone · Figure 4B; Orthotopic tumor model; treatment methods; associated Results

PF-562,271 plus gemcitabine · Figure 4B; Orthotopic tumor model; treatment methods; associated Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 939791-38-5
Applications FAK inhibitor
Formula C21H20F3N7O3S.C6H6O3S
Molecular Weight 665.66
SMILES
CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C.C1=CC=C(C=C1)S(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 14 mg/mL (21.03 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2 mg/mL
Vehicle
4% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PF-00562271 Research References

  1. [1] Sonoda D, Kamizaki K, Matsuo Y, et al. Characterization of morphological alterations in micropapillary adenocarcinoma of the lung using an established cell line. Oncology reports (2022). PMID: 34796907 DOI: 10.3892/or.2021.8230 Source material
  2. [2] Stokes JB, Adair SJ, Slack-Davis JK, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Molecular cancer therapeutics (2011). PMID: 21903606 DOI: 10.1158/1535-7163.mct-11-0261 Source material
  3. [3] Gioeli D, Snow CJ, Simmers MB, et al. Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells. Lab on a chip (2019). PMID: 30839006 DOI: 10.1039/c8lc00755a Source material

Publications

1 publication citing this product

  1. Dai Sonoda, .et al. , Oncol Rep, 2022, Jan;47(1):19 PMID: 34796907

Added to your cart

View Cart Checkout
Loading...